Israel Healthcare Ventures

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Lifeward is a medical device company based in Marlborough, Massachusetts, specializing in innovative solutions for individuals with lower limb disabilities. The company develops, manufactures, and markets advanced walking systems, notably the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is intended for everyday use, allowing individuals to engage in activities at home, work, and various outdoor environments. This system supports standing, sitting, and turning, while also facilitating stair climbing and descending. Lifeward's mission is to enhance the quality of life for those with spinal cord injuries by providing robotic technologies that offer significant functional and health benefits across different settings, including clinical environments and everyday life. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

OrSense Ltd. is a medical device company based in Petah-Tikva, Israel, specializing in non-invasive monitoring technologies for blood parameter measurement. Founded in 1996, the company develops solutions that enable continuous monitoring of hemoglobin, oxygen saturation, and pulse rate, utilizing its proprietary Occlusion Spectroscopy technology. The flagship product, the NBM 200MP system, allows for non-invasive measurement of multiple blood parameters, including hemoglobin, hematocrit, and low perfusion oximetry, making it suitable for use in hospitals, outpatient settings, and emergency services. OrSense's products have received CE approval and have been validated through testing on over 4,000 patients across various clinical environments in the U.S. and Europe. Their innovative approach addresses challenges such as poor peripheral perfusion and motion-induced noise, providing reliable and accurate monitoring solutions for healthcare providers.

novoGI Inc. specializes in developing innovative medical devices for gastrointestinal disease management, focusing on solutions that enhance patient care. The company has pioneered a range of nitinol-based compression anastomosis devices, which are designed to facilitate natural reconnection of the intestine following colorectal resection procedures, such as those related to colon cancer treatment. This technology represents a significant advancement in surgical closure methods, utilizing the body's natural healing processes to ensure effective tissue integration. novoGI's products are backed by clinical evidence and have received FDA clearance and CE marking, allowing their use in various healthcare settings. Founded in 1996 and headquartered in Atlanta, Georgia, novoGI also has facilities in Paris, France, and Netanya, Israel, reflecting its global presence in the medical device industry.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Mazor Robotics, founded in 2001 and headquartered in Caesarea, Israel, specializes in developing, producing, and marketing medical devices for orthopedic and neurosurgical procedures. The company's primary focus is on surgical robotic-guidance systems that enhance precision and minimize invasiveness during complex surgeries. Their flagship products include the Mazor X and Renaissance systems, which are used extensively in spine surgeries such as fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. These systems aim to provide a safer surgical environment for patients, surgeons, and operating room staff by transforming traditional freehand procedures into highly accurate, state-of-the-art operations with better clinical outcomes.

Escape Rescue Systems Ltd. is a company specializing in the development and installation of innovative evacuation systems for high-rise buildings in the United States and Israel. Founded in 2002 and based in Tel Aviv, the company offers a multi-platform rescue system that includes collapsible cabins stored on building rooftops, facilitating rapid and safe external evacuation of tenants during emergencies. This system is designed to enable quick deployment of rescue personnel to elevated floors, enhancing safety and efficiency in crisis situations. Escape Rescue Systems focuses on creating solutions that address the unique challenges posed by high-rise structures, providing essential life and fire resistance features in its offerings.

GI View Ltd. develops devices for diagnosing and treating gastrointestinal disorders. Its product includes Aer-O-Scope, a disposable, miniaturized, self-propelling, and self-navigating endoscope, which provides video images of the colon inner surface that are displayed on a screen for real time viewing. The company was founded in 2004 and is based in Ramat Gan, Israel.

OrSense Ltd. is a medical device company based in Petah-Tikva, Israel, specializing in non-invasive monitoring technologies for blood parameter measurement. Founded in 1996, the company develops solutions that enable continuous monitoring of hemoglobin, oxygen saturation, and pulse rate, utilizing its proprietary Occlusion Spectroscopy technology. The flagship product, the NBM 200MP system, allows for non-invasive measurement of multiple blood parameters, including hemoglobin, hematocrit, and low perfusion oximetry, making it suitable for use in hospitals, outpatient settings, and emergency services. OrSense's products have received CE approval and have been validated through testing on over 4,000 patients across various clinical environments in the U.S. and Europe. Their innovative approach addresses challenges such as poor peripheral perfusion and motion-induced noise, providing reliable and accurate monitoring solutions for healthcare providers.